02444nas a2200241   4500000000100000008004100001260001200042653001600054653001200070653002400082653002300106653003100129653002900160653001500189653002900204653001700233100001800250700001200268700001300280245013000293520176500423022001402188       2021                            d  c09/202110aClofazimine10aDapsone10aMolecular chaperone10aMulti drug therapy10aMycobacterium leprae HSP1810aProtein-drug interaction10aRifampicin10aSmall heat shock protein10aSpectroscopy1 aChakraborty A1 aGhosh R1 aBiswas A00aInteraction of constituents of MDT regimen for leprosy with Mycobacterium leprae HSP18: Impact on its structure and function.3 a<p>Mycobacterium leprae, the causative organism of leprosy, harbors many antigenic proteins and one such protein is the 18-kDa antigen. This protein belongs to the small heat shock protein family and is commonly known as HSP18. Its chaperone function plays an important role in the growth and survival of M. leprae inside infected hosts. HSP18/18-kDa antigen is often used as a diagnostic marker for determining the efficacy of multidrug therapy (MDT) in leprosy. However, whether MDT drugs (dapsone, clofazimine and rifampicin) do interact with HSP18 and how these interactions affect its structure and chaperone function is still unclear. Here, we report evidence of HSP18-dapsone/clofazimine/rifampicin interaction and its impact on the structure and chaperone function of HSP18. These three drugs interact efficiently with HSP18 (having sub-micromolar binding affinity) with 1:1 stoichiometry. Binding of these MDT drugs to the "α-crystallin domain" of HSP18 alters its secondary structure and tryptophan micro-environment. Furthermore, surface hydrophobicity, oligomeric size and thermostability of the protein are reduced upon interaction with these three drugs. Eventually, all these structural alterations synergistically decrease the chaperone function of HSP18. Interestingly, the effect of rifampicin on the structure, stability and chaperone function of this mycobacterial small heat shock protein is more pronounced than the other two MDT drugs. This reduction in the chaperone function of HSP18 may additionally abate M. leprae survivability during multidrug treatment. Altogether, this study provides a possible foundation for rational designing and development of suitable HSP18 inhibitors in the context of effective treatment of leprosy.</p>  a1742-4658